Assessing the associations between immunosuppressant use and COVID-19 severity in patients with autoimmune hepatitis

doi:10.4254/wjh.v18.i2.114481

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 2

This Article

(41)

(38)

(0)

(782)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Hepatol. Feb 27, 2026; 18(2): 114481
Published online Feb 27, 2026. doi: 10.4254/wjh.v18.i2.114481

Table 4 Adjusted Cox regression for associations between immunosuppression type and all-cause mortality amongst autoimmune hepatitis patients with coronavirus disease 2019

Immunosuppressant	Hazard ratio	P value	95%CI
Prednisone	0.77	0.40	0.42-1.41
Azathioprine	0.66	0.41	0.24-1.78
Budesonide	2.03	0.21	0.67-6.14
Tacrolimus	3.46	0.10	0.80-14.92
Mycophenolate mofetil	3.47	0.24	0.44-27.59
Cyclosporine	1.18	0.83	0.25-5.53

Full Size Table

Citation: Rai K, Lindquist KJ, Kornak J, Ge J. Assessing the associations between immunosuppressant use and COVID-19 severity in patients with autoimmune hepatitis. World J Hepatol 2026; 18(2): 114481
URL: https://www.wjgnet.com/1948-5182/full/v18/i2/114481.htm
DOI: https://dx.doi.org/10.4254/wjh.v18.i2.114481

Rai K, Lindquist KJ, Kornak J, Ge J. Assessing the associations between immunosuppressant use and COVID-19 severity in patients with autoimmune hepatitis. World J Hepatol 2026; 18(2): 114481 [PMID: 41809469 DOI: 10.4254/wjh.v18.i2.114481]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.